| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $7.4M | — | +461.6% |
| SG&A Expense | $2.8M | — | -23.7% |
| Operating Income | -$10.2M | — | -103.4% |
| Net Income | -$10.4M | — | -168.2% |
| EPS (Basic) | -$0.27 | — | -50.0% |
| EPS (Diluted) | -$0.27 | — | -50.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Current Assets | $918K | +175.6% | -77.6% |
| Total Assets | $7.3M | +6.7% | +71.7% |
| Current Liabilities | $17.0M | +44.1% | +379.4% |
| Total Liabilities | $17.1M | +43.7% | +369.0% |
| Stockholders' Equity | -$10.8M | -77.6% | -158.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.6M | — | -32.6% |
| Investing Cash Flow | -$174K | — | +0.0% |
| Financing Cash Flow | $5.2M | — | +394.9% |